Review



actinomycin d act d  (Selleck Chemicals)


Bioz Verified Symbol Selleck Chemicals is a verified supplier
Bioz Manufacturer Symbol Selleck Chemicals manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 95

    Structured Review

    Selleck Chemicals actinomycin d act d
    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or <t>Actinomycin</t> <t>D</t> <t>(Act.D)</t> for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.
    Actinomycin D Act D, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 151 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/act+d/Nutlin-3/pmc12865648-255-4-37
    Average 95 stars, based on 151 article reviews
    actinomycin d act d - by Bioz Stars, 2026-09
    95/100 stars

    Images

    1) Product Images from "p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer"

    Article Title: p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer

    Journal: Redox Biology

    doi: 10.1016/j.redox.2026.104043

    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or Actinomycin D (Act.D) for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.
    Figure Legend Snippet: FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or Actinomycin D (Act.D) for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.

    Techniques Used: Standard Deviation, Expressing, Transfection, Luciferase, Reporter Assay, Activation Assay, ChIP-qPCR

    Related Articles

    other:


    Article Title: Berberine increases the killing effect of pirarubicin on HCC cells by inhibiting ATG4B-autophagy pathway.
    Article Snippet: Pirarubicin (THP) is a new generation of cell cycle non-specific anthracycline-based anticancer drug.. In the clinic, THP and THP combination therapies have been shown to be effective in hepatocellular carcinoma (HCC) patients with transcatheter arterial chemoembolization (TACE) without serious side effects.. However, drug resistance limits its therapeutic efficacy.

    Article Title: E3 ligase HECTD3 promotes RNA virus replication and virus-induced inflammation via K33-linked polyubiquitination of PKR.
    Article Snippet: Act D, MG132, ISRIB were purchased from Selleck.

    Article Title: KANK4 Regulates CXCL16 Glycosylation Through TMEM260 to Modulate Microglial Activation in Sepsis-associated Encephalopathy
    Article Snippet: BV2 cells in the logarithmic growth phase (1 × 106 cells/well) were treated with 3 μg/mL Act D (Selleck, S8964) for each group.


    Article Title: NAP-seq reveals multiple classes of structured noncoding RNAs with regulatory functions
    Article Snippet: Cells were treated with 5 μg/ml Act D (Selleck, America) and harvested at 0 h, 20 min, 40 min, 1 h, 2 h, 4 h and 8 h with RNAzol.

    Article Title: E3 ligase HECTD3 promotes RNA virus replication and virus-induced inflammation via K33-linked polyubiquitination of PKR
    Article Snippet: Act D, MG132, ISRIB were purchased from Selleck.



    Similar Products

    86
    Changsheng Bio Technology Co act d
    Act D, supplied by Changsheng Bio Technology Co, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/act+d/act+d/pm42114793-99-0-4
    Average 86 stars, based on 1 article reviews
    act d - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    99
    MedChemExpress rna polymerase ii inhibitor act d
    Rna Polymerase Ii Inhibitor Act D, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/act+d/Actinomycin+D/pm41824452-354-14-22
    Average 99 stars, based on 1 article reviews
    rna polymerase ii inhibitor act d - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    98
    MedChemExpress actinomycin d act d
    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or <t>Actinomycin</t> <t>D</t> <t>(Act.D)</t> for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.
    Actinomycin D Act D, supplied by MedChemExpress, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/act+d/5-Fluorouracil/pmc12865648-255-4-26
    Average 98 stars, based on 1 article reviews
    actinomycin d act d - by Bioz Stars, 2026-09
    98/100 stars
      Buy from Supplier

    95
    Selleck Chemicals actinomycin d act d
    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or <t>Actinomycin</t> <t>D</t> <t>(Act.D)</t> for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.
    Actinomycin D Act D, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/act+d/Nutlin-3/pmc12865648-255-4-37
    Average 95 stars, based on 1 article reviews
    actinomycin d act d - by Bioz Stars, 2026-09
    95/100 stars
      Buy from Supplier

    96
    Selleck Chemicals act d
    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or <t>Actinomycin</t> <t>D</t> <t>(Act.D)</t> for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.
    Act D, supplied by Selleck Chemicals, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/act+d/Actinomycin+D/pmc12992473-177-16-18
    Average 96 stars, based on 1 article reviews
    act d - by Bioz Stars, 2026-09
    96/100 stars
      Buy from Supplier

    86
    I-Stat Corporation 182 jo urn al pr e p roo f 12 d i stat act kaolin test kit
    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or <t>Actinomycin</t> <t>D</t> <t>(Act.D)</t> for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.
    182 Jo Urn Al Pr E P Roo F 12 D I Stat Act Kaolin Test Kit, supplied by I-Stat Corporation, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/act+d/12+182+act+al+d+e+f+i+jo+kaolin+kit+p+pr+roo+stat+test+urn/10__1016_slash_j__jvc__2026__02__004-121-4-14
    Average 86 stars, based on 1 article reviews
    182 jo urn al pr e p roo f 12 d i stat act kaolin test kit - by Bioz Stars, 2026-09
    86/100 stars
      Buy from Supplier

    99
    Thermo Fisher transcription inhibitor act d
    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or <t>Actinomycin</t> <t>D</t> <t>(Act.D)</t> for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.
    Transcription Inhibitor Act D, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/act+d/ACTINOMYCIN+D/pm41318742-275-16-56
    Average 99 stars, based on 1 article reviews
    transcription inhibitor act d - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    99
    Thermo Fisher accountability act
    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or <t>Actinomycin</t> <t>D</t> <t>(Act.D)</t> for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.
    Accountability Act, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/act+d/ACTINOMYCIN+D/pm41203082-478-200-243
    Average 99 stars, based on 1 article reviews
    accountability act - by Bioz Stars, 2026-09
    99/100 stars
      Buy from Supplier

    98
    Thermo Fisher bvi business companies act
    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or <t>Actinomycin</t> <t>D</t> <t>(Act.D)</t> for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.
    Bvi Business Companies Act, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 98/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/act+d/ACTINOMYCIN+D/sec_filing____2001794_slash_000121390024102936_slash_ea0222438___f1a3_concorde-66-101-172
    Average 98 stars, based on 1 article reviews
    bvi business companies act - by Bioz Stars, 2026-09
    98/100 stars
      Buy from Supplier

    Image Search Results


    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or Actinomycin D (Act.D) for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.

    Journal: Redox Biology

    Article Title: p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer

    doi: 10.1016/j.redox.2026.104043

    Figure Lengend Snippet: FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or Actinomycin D (Act.D) for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.

    Article Snippet: Nutlin-3, Cisplatin, 5-fluorouracil (5-FU), actinomycin D (Act.D), Etoposide, Alrizomadlin (APG-115), Olaparib, MG132, Liproxstatin-1 (Lipro-1), Ferrostatin-1 (Ferro-1), RSL3, Z-VAD-FMK, Chloroquine (CQ), and Oxaliplatin (Oxa) were purchased from MedChemExpress (Shanghai, China), Erastin and Arachidonic acid (AA) were purchased from Selleck (Shanghai, China).

    Techniques: Standard Deviation, Expressing, Transfection, Luciferase, Reporter Assay, Activation Assay, ChIP-qPCR

    FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or Actinomycin D (Act.D) for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.

    Journal: Redox Biology

    Article Title: p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer

    doi: 10.1016/j.redox.2026.104043

    Figure Lengend Snippet: FBXO2 is a transcriptional target of p53. Data are represented as mean ± standard deviation (SD), n = 3. ∗ p < 0.05, ∗∗∗ p < 0.001, ns, not significant. See also . (A and B) qPCR analysis of the expression of FBXO2 mRNA in HCT116 p53+/+ (A) and RKO (B) cells treated with or without 5-fluorouracil (5-FU, 40 μM), Etoposide (20 μM), Nutlin-3 (20 μM), or Alrizomadlin (APG-115, 2 μM) for 24 h (C and D) IB analysis of FBXO2 protein expression in HCT116 p53+/+ (C) and RKO (D) cells treated with or without 5-FU, Etoposide, Nutlin-3, or Actinomycin D (Act.D) for 24 h (E and F) qPCR (E) and IB (F) analyses of FBXO2 expression in HCT116 p53−/− cells transfected with the indicated plasmids. (G – J) qPCR (G and I) and IB (H and J) analyses of FBXO2 expression in HCT116 p53+/+ and RKO cells treated with the siRNAs and agents as indicated. (K and L) IB analysis of FBXO2 protein expression in HCT116 p53−/− (K) and HT-29 (with p53-R273H) (L) cells treated with or without the indicated agents. (M) The schematic of the potential p53-responsive element (p53-RE) on the FBXO2 promoter. (N) The luciferase reporter assay verifies the activation of the FBXO2 promoter by p53. (O) ChIP-qPCR analysis confirms the association of p53 with p53-RE on the promoter.

    Article Snippet: Nutlin-3, Cisplatin, 5-fluorouracil (5-FU), actinomycin D (Act.D), Etoposide, Alrizomadlin (APG-115), Olaparib, MG132, Liproxstatin-1 (Lipro-1), Ferrostatin-1 (Ferro-1), RSL3, Z-VAD-FMK, Chloroquine (CQ), and Oxaliplatin (Oxa) were purchased from MedChemExpress (Shanghai, China), Erastin and Arachidonic acid (AA) were purchased from Selleck (Shanghai, China).

    Techniques: Standard Deviation, Expressing, Transfection, Luciferase, Reporter Assay, Activation Assay, ChIP-qPCR